West Pharma Crushes Q1 Earnings: EPS Jumps 56% on GLP-1 Boom

West Pharmaceutical Services (NYSE: WST) delivered a blockbuster first quarter, with earnings per share soaring 56.1% to $1.92 as the company capitalized on surging demand for components used in GLP-1 obesity drugs and other injectable medicines. The pharmaceutical packaging giant raised its full-year guidance after revenue jumped 21% to $844.9 million.

Key Numbers

The standout metric from West's first quarter was the explosive 56.1% surge in diluted earnings per share to $1.92, while adjusted EPS climbed 46.9% to $2.13. This earnings explosion came on the back of impressive top-line growth, with revenue increasing 21% to $844.9 million, or 15.3% on an organic basis excluding acquisitions and currency impacts.

The company's High-Value Product (HVP) Components business emerged as the growth engine, with sales rocketing 29.6% to $409.3 million. This segment, which includes components for GLP-1 drugs like Ozempic and Wegovy, now represents 48% of total company revenue, up from previous quarters. Management specifically noted "double-digit growth in both GLP-1 and non-GLP-1 revenues," signaling broad-based demand beyond just the obesity drug market.

Operating margin expanded dramatically to 21% from 15.3% a year ago, demonstrating strong pricing power and operational leverage. The company generated $89.9 million in operating cash flow despite investing $42.7 million in capital expenditures to expand capacity, resulting in free cash flow of $47.2 million.

Reflecting confidence in the business, West repurchased 1.2 million shares for $297.6 million at an average price of $243.57 during the quarter, a significant capital return to shareholders.

What Management Said

CEO Eric Green struck an notably optimistic tone, attributing the "better-than-expected performance" to continued market demand and the team's "outstanding efforts in ramping up production, especially in Europe." His comments suggest the company is successfully scaling operations to meet surging customer orders.

"Our revenues grew 15% organically, driven by our High Value Products Components business with double-digit growth in both GLP-1 and non-GLP-1 revenues," Green stated, emphasizing that growth extends beyond just the blockbuster obesity drug market.

The raised guidance implies management sees sustained momentum through 2026. The company increased full-year revenue guidance to $3.295-$3.350 billion from $3.215-$3.275 billion previously, representing 7-9% organic growth. More impressively, adjusted EPS guidance jumped to $8.40-$8.75 from $7.85-$8.20, a substantial increase that suggests margins will remain elevated.

For the second quarter, management guided to revenue of $830-$850 million, implying 7-9.6% organic growth, with adjusted EPS of $2.05-$2.12, up 11.4-15.2% year-over-year. This guidance suggests the strong performance will continue, though at a slightly more moderate pace than Q1's blowout results.

What to Watch

The pending sale of the SmartDose 3.5mL platform to AbbVie, expected to close mid-year, represents a key milestone. This asset generated $55 million in revenue in the second half of 2025, and its divestiture is already factored into guidance, suggesting minimal disruption to the growth trajectory.

Capacity expansion remains critical as West races to meet demand. The company maintained its capital spending guidance at $250-$275 million for 2026, signaling continued investment in manufacturing capabilities. With management highlighting successful production ramps in Europe, investors should monitor whether West can maintain its operational execution while scaling rapidly.

The GLP-1 opportunity appears far from exhausted. With obesity drug sales expected to reach $100+ billion by decade's end, West's position as a key supplier of injection components positions it to capture significant value. However, investors should watch for any signs of customer inventory adjustments or competitive pressures that could moderate the current growth trajectory.

The West Vantage segment, representing 18% of sales, grew a more modest 6.2% organically but showed strength in self-injection devices for obesity and diabetes. This diversification provides some cushion should growth in the core components business moderate.

Perhaps most notably, the dramatic margin expansion to 21% operating margin from 15.3% a year ago suggests significant operating leverage in the business model. If West can sustain these margins while growing revenue high-single to low-double digits, the earnings growth could continue to outpace revenue growth substantially.

The company's strong free cash flow generation and aggressive share buyback program signal management's confidence in the sustainability of current performance levels. With the stock trading at elevated valuations following its strong run, execution will be paramount to justify the premium multiple.

StockCliff Research